Merck & Co. to Acquire WuXi Biologics' Vaccine Facility in Ireland for $500 Million
• Merck & Co. has announced the acquisition of WuXi Biologics' vaccine manufacturing facility in Ireland for $500 million, expanding its production capabilities.
• The acquisition will allow Merck to enhance its vaccine manufacturing capacity to meet growing global demand for critical vaccines.
• WuXi Biologics' sale of the Ireland facility aligns with its strategic focus on other areas of biopharmaceutical development and manufacturing.
• The deal is expected to close in the coming months, pending regulatory approvals and customary closing conditions.
© Copyright 2025. All Rights Reserved by MedPath